Poor adherence to lipid-lowering therapy [59], low-density lipoprotein (LDL) L5 and pro-protein convertase subtilisin/kexin type 9 (PCSK9)-related lipid dysregulation, and insulin resistance may underlie this relationship [60,61]. Here, PCSK9 is linked to Insulin resistance.